October 27, 2020Open Access

A combined clinical and biological risk classification improves prediction of outcome in hepatoblastoma patients

SCStefano CairoInformatique, BioInformatique, Systèmes Complexes CACarolina ArmengolCentre for Biomedical Network Research on Rare Diseases RMRudolf MaibachFoundation Medical Partners

Key Points

Key points are not available for this paper at this time.

Abstract

We propose a new stratification system based on the combination of clinical factors and the 16-gene signature, which may facilitate a risk-adapted management of HB patients.

KI fragen

Bookmark

View Full Paper

Cite This Study

Cairo et al. (Tue,) studied this question.

synapsesocial.com/papers/69debca440ea06567955946b https://doi.org/https://doi.org/10.1016/j.ejca.2020.09.026

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cancer related mutations in <i>NRF2</i> impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy2008 · 725 citations
2The -Catenin Destruction Complex2012 · 1,063 citations
3Primary hepatic tumors of childhood1983 · 508 citations
4Wnt signalling and its impact on development and cancer2008 · 1,636 citations
5High Dose Chemotherapy with Autologous Stem Cell Transplantation in Hepatoblastoma does not Improve Outcome. Results of the GPOH Study HB992019 · 27 citations

KI fragen

Bookmark

View Full Paper